This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Humana (HUM) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Humana (HUM) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Humana (HUM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.
Boston Scientific (BSX) Q3 Earnings to Grow on Vital Procedures
by Zacks Equity Research
Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.
Teladoc's (TDOC) Telemedicine Service to Improve Mental Health
by Zacks Equity Research
Teladoc Health (TDOC) rolls out a new telemedicine solution to address mental health issues of Canadian employees.
Higher Testing Volume to Aid LabCorp's (LH) Q3 Earnings
by Zacks Equity Research
In Q3, LabCorp (LH) significantly expands accessibility of PCR testing to reach underserved communities.
UnitedHealth (UNH) Up 33% in a Year: What's Aiding the Stock?
by Zacks Equity Research
UnitedHealth Group (UNH) continues to benefit from rolling out of cost-effective health plans and a strong balance sheet, which have been aiding its share price.
Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (HUM) Outperforming Other Medical Stocks This Year?
Higher Testing to Aid Quest Diagnostics' (DGX) Q3 Earnings
by Zacks Equity Research
Quest Diagnostics (DGX) is expected to report strong improvement in COVID-19 antibody and molecular diagnostic testing volume in Q3.
Humana (HUM) Expands in Tennessee to Boost Medicare Business
by Zacks Equity Research
Humana (HUM) expands Medicare Advantage in 31 rural counties of the Knoxville, Memphis, Nashville regions as well as drives benefits for veterans.
COVID-19 Antigen Test Launch to Drive Abbott (ABT) Q3 Earnings
by Zacks Equity Research
Abbott (ABT) is expected to register strong sales in the Adult Nutrition category, banking on growing global demand for its nutrition brand Ensure.
Humana Adds Retail Pharmacies to Medicare Part D Network
by Zacks Equity Research
Humana (HUM) adds Kroger Health and its chain of pharmacies to its preferred stand-alone Medicare Part D pharmacy network, to be effective 2021.
UnitedHealth's (UNH) Earnings in Q3 Beat on Higher Revenues
by Zacks Equity Research
UnitedHealth's (UNH) Q3 earnings top estimates on solid revenues but the same was down year over year as health care utilization is resuming normalcy.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the third quarter, Thermo Fisher (TMO) invests more than $140 million to increase the production of its laboratory plastic consumables.
Cigna Set to Grab a Bigger Pie of Medicare Advantage Business
by Zacks Equity Research
Cigna's (CI) Medicare Advantage expansion in new counties and states with attractive prices and a suite of product and service offerings holds promise to widen its market share.
UnitedHealth Expands Offers to Tap Medicare Advantage Market
by Zacks Equity Research
UnitedHealth's (UNH) Medicare Advantage expansion in new counties and states with attractive price and a slew of product and service offerings to grow its market share.
What's in the Offing for UnitedHealth (UNH) Earnings in Q3?
by Zacks Equity Research
UnitedHealth's (UNH) Q3 results are likely to reflect a rise in revenues but a decline in earnings.
Will Walgreens (WBA) Post Dull Retail Numbers in Q4 Earnings?
by Zacks Equity Research
Walgreens' (WBA) retail pharmacy international sales remain dull in Q4 on difficult market scenario in the U.K.
Humana Expands Medicare Plans to Boost New Jersey Footprint
by Zacks Equity Research
Humana's (HUM) 2021 Medicare Advantage plans will not only expand its presence in New Jersey but also provide improved health outcomes.
Humana (HUM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Humana (HUM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Humana's (HUM) MA Members Gain From Better Health Outcomes
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage patients enjoy value-based heathcare at reasonable costs.
Teladoc (TDOC) Stock Soars 166% YTD: More Room for Upside?
by Zacks Equity Research
Teladoc (TDOC) continues to benefit from increased telehealth visits and a strong balance sheet, which have been aiding its share price.
Centene's 2021 Medicare Plans to Strengthen U.S. Footprint
by Zacks Equity Research
Centene's (CNC) 2021 health plans will not only expand its presence by 30% in the United States but also provide improved health outcomes for its members.
Humana, FMCNA Expand Services for Better Health Outcomes
by Zacks Equity Research
Humana (HUM) expands agreement with Fresenius Medical Care North America to provide better healthcare for Humana Medicare Advantage and commercial members with CKD and ESRD.
Walmart Ups Health Care Game With Walmart Insurance Services
by Zacks Equity Research
Walmart (WMT) will provide Medicare insurance through Walmart Insurance Services starting on Oct 15.